Anna Wald
Professor (Tenured)
Department of Medicine, Division of Allergy & Infectious Diseases
Professor
Department of Epidemiology
Professor
Department of Laboratory Medicine & Pathology
Head, Division of Allergy and Infectious Diseases
Member, Vaccines & Infectious Diseases Division (VIDD), Fred Hutchinson Cancer Research Center
Director, UW Virology Research Clinic
Attending Physician
Sites of Practice: 
Harborview Medical Center
Seattle Cancer Care Alliance

Faculty Information

Biography
Honors: 
Phi Beta Kappa, Wesleyan University
1979
American Social Health Association Fellowship
1994
The Clinical Research Meeting Trainee Investigator Award
1995
University of Washington STD CRC New Investigator Award
1994
Fialkow Scholar Award
2000
ASTDA Achievement Award
2004
UW Medicine Award for Excellence in Mentoring Women and Minorities
2006
Association of American Physicians
2010
Award for Scientific Advancement, Association for Women in Science, Seattle
2014
WSCI Outstanding Investigator Award
2014
ASTDA Distinguished Career Award
2015
31st Annual Indiana University Sch of Medicine Sexually Transmitted Diseases Lecture
2017
Mount Sinai Alumni Saul Horowitz, Jr, Memorial Award
2019
IDSA Foundation’s Woman of ID
2019
International Society for Antiviral Research Women in Science Speaker
2020
IDSA John F. Enders Lectureship
2020
Contact
Phone: 
(206) 520-4340
Mailing Address: 

Harborview Medical Center
325 9th Ave
Box 359928

Seattle, WA 98104

Research & Clinical Interests
Research Interests: 
  • Herpesvirus infections
  • Clinical epidemiology
  • Clinical trials
  • Vaccine development
Clinical Interests: 
  • Clinical virology
  • Sexually transmitted diseases
  • Infections in immunocompromised host
Publications
Publications: 

Barnabas RV, Brown ER, Bershteyn A, Stankiewicz Karita HC, Johnston C, Thorpe LE, Kottkamp A, Neuzil KM, Laufer M, Deming M, Paasche-Orlow MK, Kissinger PJ, Luk A, Paolino K, Landovitz RJ, Hoffman R, Schaafsma TT, Krows ML, Thomas KK, Morrison S, Haugen HS, Kidoguchi L, Wener M, Greninger AL, Huang M-L, Jerome KR, Wald A, Celum C, Chu HY, Baeten JM; Hydroxychloroquine COVID-19 PEP Study Team.  Hydroxychloroquine for post-exposure prophylaxis to prevent acute respiratory syndrome coronavirus 2 (SARS-cov-2) infection: A randomized trial. Ann Int Med 2021;174(3):344.

Boonyaratanakornkit J, Morishima C, Selke S, Zamora D, McGuffin S, Shapiro AE, Campbell VL, McClurkan CL, Jing L, Gross R, Liang J, Postnikova E, Mazur S, Chaudhary A, Das MK, Fink SL, Bryan A, Greninger AL, Jerome KR, Holbrook MR, Gernsheimer TB, Wener MH, Wald A*, Koelle DM*. Clinical, laboratory, and temporal predictors of neutralizing antibodies to SARS-CoV-2 after COVID-19. (*co-senior authors) J Clin Invest.  2021;131(3):e144930. 

Yu KKQ, Fischinger S, Smith MT, Atyeo C, Cizmeci D, Wolf CR, Layton ED, Logue JK, Aguilar MS, Shuey K, Loos C, Yu J, Franko N, Choi RY, Wald A, Barouch DH, Koelle DM, Lauffenburger D, Chu HY, Alter G, Seshadri C.  T cell and antibody functional correlates of severe COVID-19.  medRxiv. 2020 Nov 30:2020.11.25.20235150.  doi: 10.1101/2020.11.25.20235150. Preprint.

Phan IQ, Subramanian S, Kim D, Carter L, King N, Anishchenko I, Barrett LK, Craig J, Tillery L, Shek R, Harrington WE, Koelle DM, Wald A, Boonyaratanakornkit J, Isoherranen N, Greninger AL, Jerome KR, Chu H, Staker B, Stewart L, Myler PJ, Van Voorhis WC.  In silico detection of SARS-CoV-2 specific B-cell epitopes and validation in ELISA for serological diagnosis of COVID-19.  Scientific Reports.  2021;11(1):4290

Elyanow R, Snyder TM, Dalai SC, Gittelman RM, Boonyaratanakornkit J, Wald A, Selke S, Wener MH, Morishima C, Greninger A, Holbrook MR, Kaplan IM, Carlson JM, Zahid HJ, Baldo L, Manley T, Robins H, Koelle DM. 2021. T-cell receptor sequencing identifies prior SARS-CoV-2 infection and correlates with neutralizing antibody titers and disease severity.  Preprint posted as https://www.medrxiv.org/content/10.1101/2021.03.19.21251426v1. PMID 33791723.

Johnston C, Brown ER, Stewart J, Karita HCS, Kissinger PJ, Dwyer J, Hosek S, Oyedele T, Paasche-Orlow MK, Paolino K, Heller KB, Leingang H, Haugen HS, Dong TQ, Bershteyn A, Sridhar AR, Poole J, Noseworthy PA, Ackerman MJ, Morrison S, Greninger AL, Huang ML, Jerome KR, Wener MH, Wald A, Schiffer JT, Celum C, Chu HY, Barnabas RV, Baeten JM; COVID-19 Early Treatment Study Team. Hydroxychloroquine with or without azithromycin for treatment of early SARS-CoV-2 infection among high-risk outpatient adults: A randomized clinical trial. EClinicalMedicine. 2021;33:100773.